PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsGuanfacine
Tenex, Intuniv(guanfacine)
Guanfacine, Intuniv (guanfacine) is a small molecule pharmaceutical. Guanfacine was first approved as Tenex on 1986-10-27. It is used to treat attention deficit disorder with hyperactivity and hypertension in the USA. It has been approved in Europe to treat attention deficit disorder with hyperactivity.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
mental disordersD001523
Trade Name
FDA
EMA
Guanfacine, Intuniv (discontinued: Guanfacine, Tenex)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Guanfacine hydrochloride
Tradename
Company
Number
Date
Products
INTUNIVTakedaN-022037 RX2009-09-02
4 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
guanfacineANDA2025-10-02
guanfacine erANDA2025-01-22
guanfacine extended-releaseANDA2025-09-30
guanfacine hydrochlorideANDA2025-07-24
intunivNew Drug Application2025-06-23
tenexNew Drug Application2013-05-08
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hypertensionEFO_0000537D006973I10
attention deficit disorder with hyperactivityEFO_0003888D001289F90
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C02: Antihypertensives
— C02A: Antiadrenergic agents, centrally acting
— C02AC: Imidazoline receptor agonists
— C02AC02: Guanfacine
HCPCS
No data
Clinical
Clinical Trials
94 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Attention deficit disorder with hyperactivityD001289EFO_0003888F90121014835
HypertensionD006973EFO_0000537I101—2137
HyperkinesisD006948———11226
SyndromeD013577———1—225
AggressionD000374EFO_0003015————314
PainD010146EFO_0003843R52———123
Cognitive dysfunctionD060825—G31.84—2—1—3
Autistic disorderD001321EFO_0003758F84.0———213
Sleep initiation and maintenance disordersD007319—F51.01———112
SchizophreniaD012559EFO_0000692F20———112
Show 43 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Critical illnessD016638———11——2
DeliriumD003693—R41.0—11——2
Mental disordersD001523EFO_0000677F91.9——1—12
Alzheimer diseaseD000544EFO_0000249F03——1——1
Rare diseasesD035583————1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AlcoholismD000437EFO_0003829F10.133———5
Impulsive behaviorD007175———1——23
Down syndromeD004314EFO_0001064Q90—1——12
Smoking cessationD016540EFO_0004319——2———2
Substance-related disordersD019966EFO_0003890F1311———2
Alcohol drinkingD000428EFO_0004329——2———2
SmokingD012907EFO_0004318——2———2
Marijuana abuseD002189EFO_0007191F1211———2
Cocaine-related disordersD019970—F1411———2
Trigeminal neuralgiaD014277EFO_1001219G50.0—1———1
Show 10 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———3————3
Pure autonomic failureD054970——1————1
Post-traumatic stress disordersD013313EFO_0001358F43.11————1
Opioid-related disordersD009293EFO_0005611F111————1
MindfulnessD064866——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382—U07.1————22
BursitisD002062EFO_1000941M71.9————22
HemorrhageD006470MP_0001914R58————11
Heart failureD006333EFO_0003144I50————11
InfectionsD007239EFO_0000544—————11
Coronavirus infectionsD018352EFO_0007224B34.2————11
MenorrhagiaD008595EFO_0003945N92.0————11
Hemophilia aD006467EFO_0007267D66————11
PneumoniaD011014EFO_0003106J18————11
Blood coagulation disordersD001778EFO_0009314D68.9————11
Show 23 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameGuanfacine
INNguanfacine
Description
Guanfacine is a member of acetamides.
Classification
Small molecule
Drug classantihypertensives (guanidine deriviatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
Identifiers
PDB—
CAS-ID29110-47-2
RxCUI—
ChEMBL IDCHEMBL862
ChEBI ID5558
PubChem CID3519
DrugBankDB01018
UNII ID30OMY4G3MK (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Intuniv – Shire
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Intuniv – Takeda
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Guanfacine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 3,719 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
4,258 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use